AMIX
Autonomix Medical, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Last price
5.27
■ 0.00 (0.00%)
MARKET · —
Price
Too many bars for candle bodies at this width — showing high/low range per bar. Zoom in or pick a shorter range.
Open
5.38
Prev close
5.27
Day high
5.87
Day low
5.19
Volume
108.72K
Market cap
$5.12M
P/E (TTM)
—
52W range
2.44 – 32.55
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
22.30K
Total on file
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Trailing performance
Returnvs SPY
1W
-23.07%
-21.7%
1M
+50.57%
+46.8%
3M
-37.10%
-40.2%
6M
-33.79%
-44.9%
YTD
-54.37%
-66.7%
1Y
-76.10%
-96.1%
3Y
—
-74.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$5.12M
Enterprise value$1.66M
Revenue (TTM)—
Gross profit—
EBITDA$-16.37M
Net income$-16.11M
EPS (TTM)$-31.05
Free cash flow$-7.62M
Total cash$3.46M
Total debt$0
Book value / share$5.83
Shares outstanding971.04K
Float940.90K
Short % of float50.11%
Dividend yield—
Beta (5Y)-1.16
Short interest
Shares short
263.44K
Prior 16.48K
Change vs prior
+1,498.9%
Shorts adding
% of float
50.11%
Heavily shorted
% of shares out
48.52%
Against total outstanding
Days to cover
0.1
Liquid
Float
940.90K
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Valuation & profitability ratios
Trailing P/E—
Forward P/E-0.71
PEG ratio—
Price / sales—
Price / book0.90
EV / revenue—
EV / EBITDA-0.10
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-315.99%
Return on assets-157.81%
Debt / equity—
Current ratio4.85
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $7.14M | $4.72M | $2.23M | $745.00K | +51.2% |
| Selling, general & admin | $9.89M | $6.86M | $5.25M | $1.25M | +44.1% |
| Total operating expense | $17.03M | $11.59M | $7.47M | $1.99M | +47.0% |
| Operating income | -$17.03M | -$11.59M | -$7.47M | -$1.99M | -47.0% |
| Net interest income | $319.00K | $178.00K | $48.00K | $0 | +79.2% |
| Pre-tax income | -$16.71M | -$11.41M | -$15.43M | -$1.99M | -46.5% |
| Tax provision | $0 | $0 | $0 | $0 | — |
| Net income | -$16.71M | -$11.41M | -$15.43M | -$1.99M | -46.5% |
| Net income to common | -$16.71M | -$11.41M | -$15.43M | -$1.99M | -46.5% |
| Basic EPS | -48.72 | -135.66 | -311.22 | -39.58 | +64.1% |
| Diluted EPS | -48.72 | -135.66 | -311.22 | -39.58 | +64.1% |
| EBIT | -$16.71M | -$11.23M | -$15.35M | -$1.99M | -48.8% |
| EBITDA | -$16.70M | -$11.05M | -$15.27M | -$1.99M | -51.1% |
| Basic shares | 343.65K | 84.11K | 49.56K | 50.28K | +308.6% |
| Diluted shares | 343.65K | 84.11K | 49.56K | 50.28K | +308.6% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $7.00M | $9.14M | $8.61M | $865.00K | -23.3% |
| Cash & short-term investments | $7.00M | $9.14M | $8.61M | $865.00K | -23.3% |
| Total current assets | $7.58M | $9.61M | $9.39M | $865.00K | -21.1% |
| Property, plant & equipment | $19.00K | $21.00K | $16.00K | $0 | -9.5% |
| Total assets | $7.60M | $9.81M | $9.41M | $865.00K | -22.5% |
| Total current liabilities | $1.71M | $1.71M | $777.00K | $221.00K | -0.1% |
| Long-term debt | — | — | $1.00M | — | — |
| Total debt | — | — | $1.00M | — | — |
| Total liabilities | $1.71M | $1.71M | $1.78M | $221.00K | -0.1% |
| Retained earnings | -$67.09M | -$50.38M | -$38.97M | -$23.54M | -33.2% |
| Shareholder equity | $5.89M | $8.10M | $7.63M | $644.00K | -27.2% |
| Working capital | $5.88M | $7.90M | $8.61M | $644.00K | -25.6% |
| Net tangible assets | $5.89M | $8.10M | $7.63M | $644.00K | -27.2% |
| Shares issued | 543.30K | 118.91K | 44.87K | 50.28K | +356.9% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Net income | -$16.71M | -$11.41M | -$15.43M | -$1.99M | -46.5% |
| Depreciation & amortisation | $12.00K | $183.00K | $81.00K | $0 | -93.4% |
| Stock-based compensation | $796.00K | $1.63M | $618.00K | $0 | -51.1% |
| Change in working capital | -$107.00K | $1.24M | $79.00K | $136.00K | -108.6% |
| Operating cash flow | -$12.28M | -$8.26M | -$6.65M | -$1.85M | -48.7% |
| Capital expenditure | -$10.00K | -$14.00K | -$19.00K | — | +28.6% |
| Investing cash flow | -$10.00K | -$14.00K | -$19.00K | $0 | +28.6% |
| Financing cash flow | $10.16M | $8.80M | $14.41M | $675.00K | +15.5% |
| Free cash flow | -$12.29M | -$8.27M | -$6.67M | -$1.85M | -48.6% |
| End cash position | $7.00M | $9.14M | $8.61M | $865.00K | -23.3% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $1.46M | $1.72M | $2.37M | $1.59M | $1.55M | — | -15.3% |
| Selling, general & admin | $1.28M | $1.62M | $5.17M | $1.83M | $1.70M | — | -21.1% |
| Total operating expense | $2.74M | $3.34M | $7.53M | $3.42M | $3.25M | — | -18.1% |
| Operating income | -$2.74M | -$3.34M | -$7.53M | -$3.42M | -$3.25M | — | +18.1% |
| Net interest income | $71.00K | $82.00K | $83.00K | $84.00K | $61.00K | — | -13.4% |
| Pre-tax income | -$2.67M | -$3.26M | -$7.45M | -$3.34M | -$3.19M | — | +18.2% |
| Tax provision | $0 | $0 | $0 | $0 | $0 | — | — |
| Net income | -$2.67M | -$3.26M | -$7.45M | -$3.34M | -$3.19M | — | +18.2% |
| Net income to common | -$2.67M | -$3.26M | -$7.45M | -$3.34M | -$3.19M | — | +18.2% |
| Basic EPS | — | -7.56 | -28.98 | -22.47 | — | -30.66 | — |
| Diluted EPS | — | -7.56 | -28.98 | -22.47 | — | -30.66 | — |
| EBIT | -$2.67M | -$3.26M | -$7.45M | -$3.34M | -$3.15M | — | +18.2% |
| EBITDA | -$2.66M | -$3.26M | -$7.45M | -$3.33M | -$3.10M | — | +18.2% |
| Basic shares | — | 426.47K | 257.70K | 147.86K | — | 88.19K | — |
| Diluted shares | — | 426.47K | 257.70K | 147.86K | — | 88.19K | — |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $7.00M | $9.93M | $7.48M | $8.59M | $9.14M | — | -29.5% |
| Cash & short-term investments | $7.00M | $9.93M | $7.48M | $8.59M | $9.14M | — | -29.5% |
| Total current assets | $7.58M | $10.19M | $7.89M | $8.98M | $9.61M | — | -25.6% |
| Property, plant & equipment | $19.00K | $20.00K | $16.00K | $19.00K | $21.00K | — | -5.0% |
| Total assets | $7.60M | $10.21M | $7.93M | $9.00M | $9.81M | — | -25.6% |
| Total current liabilities | $1.71M | $1.65M | $1.49M | $1.97M | $1.71M | — | +3.3% |
| Current debt | — | — | — | — | — | $1.13M | — |
| Total debt | — | — | — | — | — | $1.13M | — |
| Total liabilities | $1.71M | $1.65M | $1.49M | $1.97M | $1.71M | — | +3.3% |
| Retained earnings | -$67.09M | -$64.43M | -$61.17M | -$53.72M | -$50.38M | — | -4.1% |
| Shareholder equity | $5.89M | $8.56M | $6.45M | $7.03M | $8.10M | — | -31.1% |
| Working capital | $5.88M | $8.54M | $6.41M | $7.01M | $7.90M | — | -31.2% |
| Net tangible assets | $5.89M | $8.56M | $6.45M | $7.03M | $8.10M | — | -31.1% |
| Shares issued | 543.30K | 543.30K | 294.96K | 191.55K | 118.91K | — | 0.0% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$2.67M | -$3.26M | -$7.45M | -$3.34M | -$3.19M | — | +18.2% |
| Depreciation & amortisation | $3.00K | $4.00K | $2.00K | $3.00K | $48.00K | — | -25.0% |
| Stock-based compensation | $1.00K | $2.00K | $405.00K | $388.00K | $405.00K | — | -50.0% |
| Change in working capital | -$230.00K | $286.00K | -$505.00K | $342.00K | $229.00K | — | -180.4% |
| Operating cash flow | -$2.89M | -$2.97M | -$3.82M | -$2.60M | -$2.51M | — | +2.6% |
| Capital expenditure | -$3.00K | — | — | — | -$4.00K | -$5.00K | — |
| Investing cash flow | -$3.00K | -$7.00K | $0 | $0 | -$4.00K | — | +57.1% |
| Financing cash flow | -$35.00K | $5.43M | $2.71M | $2.06M | -$174.00K | — | -100.6% |
| Free cash flow | -$2.90M | -$2.98M | -$3.82M | -$2.60M | -$2.51M | — | +2.7% |
| End cash position | $7.00M | $9.93M | $7.48M | $8.59M | $9.14M | — | -29.5% |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Mar 2026 | -5.46 | — | — |
| Dec 2025 | -9.66 | -7.56 | +21.7% |
| Sep 2025 | -31.50 | -28.98 | +8.0% |
| Jun 2025 | -20.58 | -22.47 | -9.2% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -6.41 | 2 | $0 | 0.0% |
| Next quarter | -6.20 | 2 | $0 | 0.0% |
| Current year | -22.68 | 2 | $0 | 0.0% |
| Next year | -19.53 | 2 | $0 | 0.0% |
Analyst targets & ownership
Mean target$58.80
High target$75.60
Low target$42.00
Implied upside1015.75%
Analyst count2
ConsensusNONE
Strong buy / Buy1 / 1
Hold0
Sell / Strong sell0 / 0
Held by insiders2.30%
Held by institutions5.81%
Institutions holding7
Price targets, consensus spread, insider and institutional ownership.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 17, 26 | Maxim Group | MAINTAINED | Buy | Buy |
| Apr 29, 25 | Maxim Group | INITIATED | — | Buy |
| Sep 3, 24 | Ladenburg Thalmann | INITIATED | — | Buy |
Moving averages & technicals
SMA 10
6.87
-23.26% from price
SMA 20
7.16
-26.44% from price
SMA 50
6.59
-20.02% from price
SMA 100
7.27
-27.49% from price
SMA 200
9.73
-45.83% from price
EMA 12
6.68
-21.07% from price
EMA 26
6.79
-22.44% from price
EMA 50
6.87
-23.26% from price
RSI (14)
44.7
Neutral
MACD (12,26,9)
-0.12
Hist -0.42
ATR (14)
3.20
60.77% of price
Realised vol 30D
547.3%
Annualised
Bollinger upper
15.08
20, 2σ
Bollinger lower
-0.75
20, 2σ
50 / 200 cross
Death
6.59 vs 9.73
Trend bias
Below 200
-45.83%
Risk profile
Beta vs SPY
5.13
More volatile than market
Correlation to SPY
0.15
Largely independent
Realised vol 30D
547.3%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-89.6%
Peak to trough
Max drawdown 5Y
-99.9%
Peak to trough
ATR 14
3.20
60.77% of price
Beta (reported)
-1.16
5Y monthly, from filing
Dividends & splits
Forward rate—
Forward yield—
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split1:21
Split dateJun 24, 2026
SEC filings
Periodic Financial Reports
10-Q · 2026-08-13
Corporate Changes & Voting Matters
8-K · 2026-07-28
Corporate Changes & Voting Matters
8-K · 2026-07-15
Corporate Changes & Voting Matters
8-K · 2026-07-10
Corporate Changes & Voting Matters
8-K · 2026-06-24
Periodic Financial Reports
10-K/A · 2026-06-15
Periodic Financial Reports
10-K · 2026-05-27
Offering Registrations
S-8 · 2026-04-02
Headlines
Autonomix Medical Completes Good Laboratory Practice (GLP) Preclinical Study, Marking Key Step Toward FDA Submission
GlobeNewswire · 10d ago
Top Premarket Decliners
MT Newswires · 17d ago
Autonomix Medical Receives U.S. Patent for Precision Neuromodulation Platform Expansion
InvestorsHub · 18d ago
BC-Most Active Stocks
Associated Press · 18d ago
Autonomix Medical Expands Precision Neuromodulation Platform with Broad New U.S. Patent Supporting Nerve Sensing, Mapping and Targeted Therapy
GlobeNewswire · 18d ago
Top Premarket Gainers
MT Newswires · 25d ago
Autonomix Medical Demonstrates Renal Nerve Sensing and Neural Activity Change in Preclinical Study
GlobeNewswire · 29d ago
Autonomix Medical Secures US Patent for Nervous System Assessment Technologies
MT Newswires · 30d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.